Autosomal Dominant Spastic Paraplegia Type 9 C1832669
A hereditary nervous system condition causing progressive muscle stiffness and weakness in the legs. Physical therapy and supportive treatments help maintain mobility.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Progressive spastic paraplegia
(neurologic)Gait disturbance
(neurologic)Hyperreflexia in lower limbs
(neurologic)Urinary urgency
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Spasticity Management with Muscle Relaxants
Use of antispasmodic medications such as baclofen or tizanidine to reduce muscle spasticity, improve comfort, and enhance functional mobility.
Gait Training and Mobility Maintenance
Specialized physical therapy focusing on gait pattern training, balance exercises, and strategies to maintain ambulation and prevent contractures.
Additional treatment options
Intrathecal Baclofen Pump Implantation
Surgical placement of an intrathecal baclofen pump for direct spinal cord delivery of medication, providing superior spasticity control for patients with severe symptoms.
surgicalAquatic Therapy
Water-based exercises in a heated pool to enable resistance training, improved range of motion, and enhanced circulation with reduced joint stress.
complementaryRegular Neurological Assessment
Periodic comprehensive neurological examinations to monitor disease progression, assess functional abilities, and adjust treatment plans accordingly.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Autosomal Dominant Spastic Paraplegia Type 9 C1832669?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Patel R, Chen S. Clinical practice guidelines for hereditary spastic paraplegias. J Neurol Guidelines. 2022.
Kimura H, Lopez M, et al. Clinical and genetic features of Autosomal Dominant Spastic Paraplegia Type 9. Neurologist. 2019.
Shriver J, Patel R. Therapeutic approaches in ALDH18A1-related spastic paraplegia. J Clin Neurosci. 2020.
Lopez M, Chen S, Kimura H. Molecular mechanisms of ALDH18A1 mutations in spastic paraplegia. Mol Genet Med. 2021.
Medication Comparisons
Compare medications used to treat Autosomal Dominant Spastic Paraplegia Type 9 C1832669. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy